Aggregator

Watch the video of our World Health Assembly side-event on using evidence to address health challenges

3 years ago

Now is the time to ‘up our game’ in using evidence to address health challenges

The COVID-19 pandemic created a once-in-a-generation focus on evidence. We now have the opportunity to systematize the aspects of evidence use that are going well and to address the many gaps.

Alongside the 75th World Health Assembly, Cochrane and the Global Commission on Evidence to Address Societal Challenges co-hosted a virtual side event which brought together a global panel to discuss some of these issues.

Speakers:

  • Dr Soumya Swaminathan, Chief Scientist, WHO
  • Fitsum Assefa Adela, Ministry of Planning and Development, Ethiopia
  • Steven J. Hoffman, member of Canada's WHA delegation; Scientific Director, CIHR Institute of Population & Public Health
  • Dr Maria Endang Sumiwi, Director General of Public Health at the Ministry of Health, Indonesia
  • John Lavis, Co-Lead, Evidence Commission
  • Dr John Grove, Director of Quality Assurance for Norms and Standards, WHO

Co-chairs:

  • Judith Brodie, Interim CEO, Cochrane
  • Sylvia de Haan, Head of Advocacy, Communications and Partnerships, Cochrane

About the session

During the roundtable, leaders from WHO Member States who use evidence to guide national decision-making were encouraged to reflect on their work – and share what they need from evidence producers, evidence intermediaries, and multilateral organizations. Cochrane, the WHO Evidence-informed Policy Network and the Evidence Commission then discussed their shared vision and recommendations.

The session was a dialogue between both the demand and supply side of evidence – highlighting the key priorities for the evidence-informed future we want and need, and the conditions needed to get us there.

 

Related links:

Friday, May 27, 2022
Muriah Umoquit

Antibiotici za sprječavanje bakterijskog endokarditisa u dentalnoj medicini

3 years ago
Antibiotici za sprječavanje bakterijskog endokarditisa u dentalnoj medicini Cilj sustavnog pregleda Ovaj Cochraneov sustavni pregled imao je za cilj otkriti trebaju li ljudi s povećanim rizikom od bakterijskog endokarditisa (teška infekcija ili upala unutarnjeg sloja srčanih komora koja može biti smrtonosna) primati antibiotike rutinski prije invazivnih stomatoloških zahvata kako bi se smanjila učestalost endokarditisa, broj smrtnih slučajeva i broj ozbiljnih bolesti. Dosadašnje spoznaje Bakterijski endokarditis je infekcija koja se obično javlja u prethodno oštećenim ili malformiranim...

COVID-19: Interventions to reduce the risk of coronavirus infection among workers outside healthcare settings

3 years ago

'Interventions to reduce the risk of coronavirus SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus‐2) infection among workers outside healthcare settings'

What is the aim of this review?

Coronavirus (COVID‐19) is a respiratory infectious disease that has spread globally. People infected with SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus‐2) can develop critical illnesses and may die, particularly older people, and those with underlying medical problems. Different interventions that attempt to prevent or reduce workers' exposure to SARS‐CoV‐2 in the workplace have been implemented during the pandemic. This Cochrane Review evaluated the effects of these interventions on the COVID‐19 infection‐rate, absenteeism, COVID‐19‐related mortality, and adverse events.  

What was studied in this review?

The authors searched for studies that examined interventions according to the following four categories: 1) elimination (for example self‐isolation strategies); 2) engineering controls (for example barriers to separate or distance co‐workers, and workers from members of the public); 3) administrative controls (for example working from home); 4) personal protective equipment (for example use of face masks or other types of face covering). We included studies of any worker outside the healthcare setting. We searched for studies without language or time restrictions. 

What are the main findings of this review?

The author team screened more than 13 thousand reports, and included one study, conducted in 162 secondary and post‐secondary schools in England, from March to June 2021. The study enrolled more than 24 thousand workers. In the 86 schools in the control group (standard isolation), staff who were considered COVID‐19 contacts through contact tracing were required to self‐isolate at home for 10 days. In the 76 schools in the intervention group (test‐based attendance), staff who were considered COVID‐19 contacts through contact tracing were not required to isolate. Instead, they took a daily rapid test (lateral flow antigen test) for seven days. If the rapid test was negative, the staff member could go to work. If the rapid test was positive, the staff member would self‐isolate. The researchers wanted to know if there was a difference in COVID‐related absence between the two methods. 

The author team are uncertain whether a strategy of test‐based attendance changes COVID‐19 infection rates (any infection; symptomatic infection) compared with routine isolation after contact with a person with COVID‐19. COVID‐related absence may be lower or similar in the test‐based attendance group. 

However, they were uncertain about these findings, because the number of infections was very low among the participants. Mortality, adverse events, quality of life, and hospitalisation were not measured. Seventy‐one per cent of the test‐based attendance group followed the strategy; the researchers did not report on compliance for the standard isolation group. 

The team identified one ongoing study that also addressed the effects of screening in schools.

Another ongoing study is evaluating the effects of using a face shield to prevent COVID‐19 transmission. 

The authors did not find any studies that studied engineering or administrative controls.

Matteo Bruschettini, Director of Cochrane Sweden, who led the review explains, 

“Millions of scientific papers are published every year, and during the pandemic there were many about covid-19. It is not an easy task to keep up to date with the results of all these. Systematic reviews are one way of weighing up all the studies carried out in a specific field and providing an overview of the results of these studies.  This review investigating how workplace interventions reduced the spread of covid-19 assessed 13, 000 scientific articles published on the subject, however only one study could be included in the review. 

Almost none of the studies had the study design required to answer the question of whether the effects of the intervention reduced the risk of SARS-CoV-2 infection in non-healthcare workplaces. This surprised us. These systematic reviews are important because they can provide answers to questions that are of extreme concern to millions of people in workplaces around the world. 

We were able to identify two studies that had not been completed by September 2021 that may be included in the future. One assesses the benefit of face shields in preventing covid infection and the other looks at covid-19 screening in schools.”

How up‐to‐date is this review?

The author team searched for studies that were available up to 14 September 2021.

 

Monday, May 9, 2022
Katie Abbotts

Terapija glazbom za osobe s poremećajima ovisnosti

3 years ago
Terapija glazbom za osobe s poremećajima ovisnosti Cilj Cochraneovog sustavnog pregleda Cilj nam je bio procijeniti je li terapija glazbom koja se pruža uz uobičajeno liječenje učinkovita za osobe s poremećajima ovisnosti, na način da utječe na smanjenje želje za sredstvima ovisnosti, da povećava motivaciju za liječenjem i motivaciju da osobe ostanu trijezne/čiste. Također nas je zanimalo postoje li dokazi o učinku na smanjenje depresije i anksioznosti, s obzirom da su ta stanja česti čimbenici rizika za povratak ovisničkim ponašanjima. Ključne poruke Terapija glazbom kao dodatak uobičajenom...

Doppler trans-torakalna ehokardiografija za otkrivanje plućne hipertenzije kod odraslih

3 years ago
Doppler trans-torakalna ehokardiografija za otkrivanje plućne hipertenzije kod odraslih Što se proučavalo u ovom sustavnom pregledu? Plućna hipertenzija je visoki krvni tlak u krvnim žilama koje opskrbljuju krv iz desne polovice srca u pluća. To je ozbiljno stanje koje može oštetiti desnu stranu srca. Stijenke krvnih žila postaju debele i krute, što otežava protok krvi. To može dovesti do zatajenja srca. Simptomi mogu uključivati otežano disanje, umor, bol u prsima, ubrzan rad srca ili oticanje donjih udova i abdomena. Simptomi mogu biti slični drugim bolestima srca i pluća, stoga je...

Cochrane seeks Director of Development - UK remote

3 years ago

Specifications: Full Time (Permanent role)
Salary: £85,000 per annum
Location: UK, homebased and remote-working (attendance at meetings will be expected to pursue development and build relations)
Application Closing Date:  Monday 6th June 2022, 9am GMT. The recruitment agency will be longlisting applications as soon as they receive them, so please apply early to register your interest. 

Cochrane aims to put evidence at the heart of health decision-making globally. They collaborate to produce trusted synthesized evidence, make it accessible to all, and advocate for its use. Cochrane is seeking a Director of Development to work with their global community to grow fundraising income and ensure Cochrane has a sustainable and successful future.

Cochrane is a charity and a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. They do this by synthesising research findings to produce the best available evidence on what works. Their work has been recognised as the international gold standard for high quality, trusted information.

As a member of the Executive Leadership Team, this new role will lead the Development Directorate (which includes fundraising, advocacy, communications, partnerships, member and supporter engagement) and will establish a fundraising operation that works collaboratively to deliver significant global income growth. The Director of Development will play a key part in the transformation of the organisation as part of the 2021-2023 Strategy to ensure that Cochrane maintains its relevance and pre-eminence into the future.

Cochrane is seeking an ambitious individual who relishes a challenge, loves collaborative working, delivers results and has extensive experience of successfully delivering strategy. The ideal candidates will possess an understanding and experience of international fundraising, strong relationship management skills, and experience of working at director-level. Finally, you will be enterprising and a strategic thinker with the ability to seek and find creative solutions and foster innovation in your teams.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to their values.


Friday, May 6, 2022 Category: Jobs
Muriah Umoquit

Intervencije za smanjenje rizika od infekcije koronavirusom SARS-CoV-2 (teški akutni respiratorni sindrom koronavirus-2) među radnicima izvan zdravstvenih ustanova

3 years ago
Intervencije za smanjenje rizika od infekcije koronavirusom SARS-CoV-2 (teški akutni respiratorni sindrom koronavirus-2) među radnicima izvan zdravstvenih ustanova Koji je cilj ovog sustavnoga pregleda? Koronavirus (COVID-19) je respiratorna zarazna bolest koja se proširila cijelim svijetom. Ljudi zaraženi sa SARS-CoV-2 (teški akutni respiratorni sindrom koronavirus-2) mogu razviti kritične bolesti i mogu umrijeti, osobito stariji ljudi i oni s višestrukim zdravstvenim problemima. Tijekom pandemije primijenjene su različite intervencije koje pokušavaju spriječiti ili smanjiti izloženost...

Koliko su točne snimke magnetske rezonancije (MR) za otkrivanje karcinoma jetre?

3 years ago
Koliko su točne snimke magnetske rezonancije (MR) za otkrivanje karcinoma jetre? Ključne poruke U osoba s kroničnom bolešću jetre magnetska rezonancija (MR: računalna tomografija tijela) vjerojatno propušta karcinom jetre u 16% osoba koje ne bi dobile pravodobno ili odgovarajuće liječenje te pogrešno pronalazi karcinom jetre u 6% osoba koje bi dobile nepotrebno liječenje. Magnetska rezonancija ne otkriva karcinom jetre u 16% osoba s karcinomom jetre kojima bi se kirurškim zahvatom mogao ukloniti dio jetre, te pogrešno pronalazi karcinom jetre u 7% osoba koje su podvrgnute nepotrebnom...

Sveobuhvatna gerijatrijska procjena za starije osobe s rizikom od nepovoljnih zdravstvenih ishoda koje žive unutar zajednice

3 years ago
Sveobuhvatna gerijatrijska procjena za starije osobe s rizikom od nepovoljnih zdravstvenih ishoda koje žive unutar zajednice Budući da se očekivani životni vijek produljio diljem svijeta, potrebno je hitno istražiti različite vrste pružanja prikladne skrbi starijim osobama kojima je ona potrebna u najprikladnijem okruženju. Mnoge starije osobe danas žive s krhkosti, kliničkim sindromom kojeg obilježava osjetljivost na nepovoljne zdravstvene ishode uključujući smrt, prijem u starački dom i gubitak neovisnosti. Željeli smo saznati povećava li organizirana i koordinirana skrb zdravstvenih...

Je li kućno ili bolničko liječenje bolje za ljude s krvnim ugrušcima u plućima?

3 years ago
Je li kućno ili bolničko liječenje bolje za ljude s krvnim ugrušcima u plućima? Ključne poruke Nije jasno je li liječenje u bolnici ili kod kuće (ambulantno) bolje za neke osobe s krvnim ugrušcima u plućima. Nisu pronađeni jasni dokazi o važnoj razlici u broju smrtnih slučajeva, krvarenja, recidiva novih krvnih ugrušaka ili zadovoljstvu pacijenata, jer su rezultati bili neprecizni, a istraživanjima se nije izvijestilo o nuspojavama na krvni tlak ili informacijama o tome koliko su ljudi dosljedno slijedili liječnički savjet. Potrebno je više dobro osmišljenih istraživanja prije nego što...

Kanabis i kanabinoidi za osobe s multiplom sklerozom

3 years ago
Kanabis i kanabinoidi za osobe s multiplom sklerozom Ključne poruke • U usporedbi s placebom, liječenje nabiksimolom vjerojatno ublažava spastičnost i vjerojatno nema više ozbiljnih štetnih učinaka od placeba • Na temelju ishoda koje su prijavili pacijenti, vjerojatno je da kanabinoidi (nabiksimol, ekstrakt kanabisa, sintetski kanabinoid) poboljšavaju zdravstveno stanje u usporedbi s placebom • Zbog nedostatka čvrstih dokaza, korist od ovih lijekova u liječenju kronične neuropatske boli ostaje upitna. Što je proučavano u ovom sustavnom pregledu? Mnoge osobe s multiplom sklerozom (MS) imaju...

Cochrane seeks Quality Assurance Editor - UK Remote Work

3 years ago

Specifications: Full Time 6 month Fixed Term contract (potential opportunity to extend)
Salary:  circa £40,000 per annum
Location: UK, Remote
Application Closing Date: 18 May 2022 (midnight GMT)

The Evidence Production and Methods Directorate in Cochrane is made up of three departments that are responsible for the efficient and timely production of high-quality Cochrane Reviews addressing research questions that are most important to decision makers.

As Quality Assurance Editor within Cochrane’s Editorial Department, you will assess whether protocols, reviews and updates submitted to Cochrane’s Central Editorial Service have met Cochrane’s methodological standards. You will recommend editorial decisions based on the quality of the methods in the articles submitted, provide feedback to authors on their articles, and support members of the Central Editorial Service with methods queries. 

Cochrane is a global independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making the vast amounts of evidence generated through research useful for informing decisions about health. We do this by identifying, appraising and synthesizing individual research findings to produce the best available evidence on what can work, what might harm and where more research is needed.

  • For further information on the role and how to apply, please click here
  • The deadline to receive your application is by 18 May 2022. 
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Read our Recruitment Privacy Statement 

Wednesday, May 4, 2022 Category: Jobs
Muriah Umoquit

Antioksidansi za liječenje smanjene plodnosti u muškaraca

3 years 1 month ago
Antioksidansi za liječenje smanjene plodnosti u muškaraca Istraživačko pitanje Poboljšavaju li oralni antioksidansi kao dodaci prehrani uspješnost liječenja smanjene plodnosti u muškaraca, u usporedbi s placebom, izostankom liječenja ili drugim antioksidansima? Dosadašnje spoznaje Može se smatrati da par ima problema s plodnošću ako bezuspješno pokušava začeti više od godinu dana. Mnogi muškarci sa smanjenom plodnošću koji se liječe od neplodnosti uzimaju i dodatke prehrani u nadi da će im oni poboljšati plodnost. Liječenje neplodnosti može biti stresno razdoblje života, kako za muškarce...

Global Evidence Summit – Postponed to 9 – 13 September 2024

3 years 1 month ago

Dear Friends and Colleagues

Due to the continued global impact of COVID-19 (coronavirus) with ongoing reduced/restricted travel from many regions, and the advent of geo-political instability and risks in the European region, we have taken the decision to postpone the Global Evidence Summit (GES 2), due to be hosted in Prague between 2 – 6 October 2023.

The Global Organising Committee (comprising four partners:  Cochrane, JBI, GIN and Campbell) concluded, with the agreement of our local host - CEBHC-KT and Masaryk University, that the most appropriate decision is to postpone the Summit until 9 – 13 September 2024. As global leaders in evidence-informed healthcare, the partners take very seriously our responsibility and duty of care to our communities in the face of continuing risks.

However, we are committed to working together, along with additional organizations, to present the third Annual World EBHC Day on 20 October, 2022. This is a global initiative that raises awareness of the need for better evidence to inform healthcare policy, practice and decision making to improve health outcomes globally.

This second postponement of the second Global Evidence Summit is disappointing news for all of us and we would like to thank the vast number of people, including our local hosts, who have been working hard on preparations over the past year. We are in no doubt that we will be able to build successfully on the work accomplished so far to ensure that when GES 2 does go ahead in September 2024 in Prague it will be everything we anticipated: a world-class scientific event and a memorable gathering of the evidence-based healthcare community. 

We thank you for your ongoing support and commitment to the Global Evidence Summit and will look forward to meeting again for this unique event in 2024. 

Recent developments have shown the world can be volatile and unpredictable, requiring us to remain vigilant and responsive – collaborations such as this are even more important.   We hope that you all remain safe and well during these extraordinary times. 

Miloslav Klugar
Director, CEBHC-KT (Czech Cochrane, JBI and GRADE centres), Chair of the GES Scientific Committee

Judith Brodie
Interim CEO, Cochrane

Zoe Jordan
Executive Director, JBI

Elaine Harrow
CEO, Guidelines International Network

Vivian Welch,
Interim CEO, The Campbell Collaboration

Wednesday, May 4, 2022
Muriah Umoquit

Global rollout of rapid molecular tests for tuberculosis over the last 12 years: Cochrane Review summarizes research on recipient and provider views

3 years 1 month ago

A potential game-changer in the tuberculosis epidemic was how the tuberculosis community viewed rapid molecular tests for tuberculosis and tuberculosis drug resistance. This was 12 years ago, with the launch of Xpert MTB/RIF, which gives results in less than two hours, simultaneously diagnosing tuberculosis and testing if the bacteria have rifampicin resistance, a type of drug-resistant tuberculosis. Multidrug-resistant tuberculosis is caused by resistance to at least both rifampicin and isoniazid, the two most effective first-line drugs used to treat tuberculosis. 

Yet, diagnostic tests only have an impact on health if they are put to use in a correct and timely manner. To ensure diagnostics are accessible and utilized, we need to understand the views of recipients and providers who have used these tests, and a new qualitative evidence synthesis review published by the Cochrane Infectious Diseases Group (CIDG) pulls together all relevant research to date on Xpert MTB/RIF and similar tests. The authors also wanted to understand the implications of the review findings on effective implementation and health equity.

Rapid molecular tests have been shown to be accurate in diagnosing tuberculosis and rifampicin resistance and are recommended by the World Health Organization as the initial test in people with presumptive tuberculosis, replacing sputum microscopy, a test from the 19th century. These tests have many benefits, including the fact that they do not require well-equipped laboratories and skilled personnel, and can be carried out in community health settings, nearer to where people live. This is particularly relevant in low- and middle-income countries, settings with a high burden of tuberculosis.

Examining the evidence from 32 included studies, the review author team identified aspects of these tests that users valued  most and challenges to realizing those values.  People with tuberculosis valued an accurate diagnosis (knowing what is wrong with me), avoiding delays, and keeping diagnostic-associated cost low. Similarly, healthcare providers valued test accuracy and confidence in results (which helps in starting treatment), rapid results, and keeping cost to people seeking a diagnosis low. In addition, providers valued diversity of sample types (for example, gastric aspirate specimens and stool in children) and ability to detect drug resistance early. Laboratory professionals appreciated the improved ease of use compared to microscopy and increased staff satisfaction.

Reported challenges included reluctance to test for tuberculosis owing to stigma or cost concerns; health system inefficiencies such as poor quality of specimens, difficulty in transporting specimens, lack of sufficient staff or equipment, increased workload for providers, inefficiencies in integrating the test into clinic routines and clinicians relying too much on the test result at expense of their own experience with diagnosing tuberculosis; as well as implementation processes hampered by insufficient  data about real-life situations, lack of inclusion of all relevant stakeholders (local decision-makers, providers or people seeking a diagnosis), and conflicts of interest between donors and people implementing the tests.

Nora Engel, lead author of the review, explains: 

“The findings reveal a fundamental paradox between supporting technological innovations but not in parallel investing in health system infrastructure strengthening. The view that these low-complexity diagnostics are a solution to overcome deficiencies in laboratory infrastructure and lack of skilled professional is misleading. Implementation of new diagnostic technologies, like those considered in this review, will need to tackle the challenges identified in this review including weak infrastructure and systems, and insufficient data on ground level realities prior and during implementation, as well as problems of conflicts of interest in order to ensure quality care and equitable use of resources.”

The review authors called for future research to examine the implications of repurposing diagnostic infrastructure and equipment for COVID-19 and the issue of competition for diagnostic resources more generally.

Engel N, Ochodo EA, Karanja PW, Schmidt BM, Janssen R, Steingart KR, et al. Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No.: CD014877. DOI: 10.1002/14651858.CD014877.pub2

This news article was first published on the LSTM website.

Monday, May 2, 2022
Muriah Umoquit

Cochrane releases RevMan Web software for non-Cochrane systematic reviews

3 years 1 month ago

Cochrane is delighted to announce the availability for the first time of RevMan Web, its popular, web-based systematic-review production software, to the wider community beyond Cochrane – to support evidence synthesis development and evidence-based medicine education. Cochrane expects interest in use of the tool from those in guideline and Health Technology Assessment organisations, universities and medical schools, and many other research sectors.

RevMan Web facilitates the creation of meta-analyses, forest plots, risk-of-bias tables, and other systematic review elements. It is acknowledged to be easy-to-use – and is also widely used in learning or training about systematic review production.

Cochrane is making RevMan Web available for use by institutions or individuals for their own systematic review development work. The product is presented on a Software-as-a-Service basis: Cochrane offers a hosted service, comprising the software and cloud storage of all review data uploaded. 

Charlotte Pestridge, Cochrane’s Director of Publishing and Technology, says this is a hugely exciting opportunity:

“Making RevMan Web more widely available is an important element in Cochrane’s contribution to healthcare research and our mission to deliver evidence-informed policy and practice through the production of systematic reviews. It is important for Cochrane to be able to support the production of high-quality reviews using Cochrane standards and methodologies. Many review-producing organisations, including key Cochrane stakeholders, already use RevMan.”

 RevMan Web is now available by subscription to government and commercial organizations. Availability for academic institutions and individual subscribers is expected to come on stream before the end of 2022. Free access will be available in Reseach4Life Hinari low and middle-income countries.

To find out more:

Wednesday, June 1, 2022
Muriah Umoquit

Cochrane seeks Evidence Synthesis Development Editor - UK

3 years 1 month ago

Specifications: Permanent
Salary: circa £45,000 per annum
Location: UK
Application Closing Date:  5 June 2022

The Evidence Production and Methods Directorate in Cochrane is made up of three departments that are responsible for the efficient and timely production of high-quality Cochrane Reviews addressing research questions that are most important to decision makers.

As Evidence Synthesis Development Editor in the Methods and Evidence Synthesis Development team, you will be working on new and updated Cochrane Reviews prior to their completion and submission for editorial process. The role-holder will need to ensure that protocols and new or updated reviews will meet Cochrane’s quality standards.

The role-holder will need to be able to recognise when to refer methodological questions to colleagues with specialist methods expertise in the Methods Support Unit or Cochrane Methods Groups for further advice, especially around the assessment of bias and statistical methods.

Cochrane is a global independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making the vast amounts of evidence generated through research useful for informing decisions about health. We do this by identifying, appraising and synthesizing individual research findings to produce the best available evidence on what can work, what might harm and where more research is needed.

How to apply

  • For further information on the role and how to apply, please click here
  • The deadline to receive your application is by 5 June 2022. 
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Read our Recruitment Privacy Statement 

Tuesday, May 24, 2022 Category: Jobs
Lydia Parsonson